bentracimab

AssetAlso called PB2452, bentracimab, MEDI-2452

Binds ticagrelor and its active metabolite to reverse antiplatelet activity.

Stage
Phase 3
Modality
Antibody
Target
Not known
7
Indications
2
Trials
3
Developers

FDA orphan designation on Mar 18, 2025.

Indications

7

4 more

In the full profile

  • Owner and partners7
  • Trials2

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets